WRITTEN QUESTION E-2090/01 by Jens-Peter Bonde (EDD) to the Commission. The Sixth Framework Programme for Research in the EU.
Date: 2001-07-13
Institutions: European Parliament, Provisional data
Subjects: EU programme, EU research policy, congenital disease, genetic engineering, health policy, infectious disease, medical research

14.2.2002

EN

Official Journal of the European Communities

C 40 E/183

Answer given by Mrs Wallstr(cid:246)m on behalf of the Commission

(20 September 2001)

The Commission has no knowledge of the problem mentioned by the Honourable Member.

For this reason it has just sent a request to the Spanish authorities for information on the facts as stated, so
as to determine the most appropriate way to implement the Community legislation applicable.

(2002/C 40 E/197)

WRITTEN QUESTION P-2087/01

by Chris Davies (ELDR) to the Commission

(5 July 2001)

Subject: European Commission office in occupied Cyprus

Will the Commission state whether it intends to open an office in the occupied part of Cyprus, and, if so,
what will be the intended purpose of this office, where is it hoped it will be located, what budget will be
allocated towards its operation, how many staff will it employ, who will manage it, and who will be this
person(cid:146)s line-manager?

If it is the intention of the Commission to open such an office, what has been the reaction of the
Government of Cyprus and of the authorities in occupied Cyprus to the proposal?

Answer given by Mr Patten on behalf of the Commission

(31 July 2001)

The Commission has a Delegation in Nicosia and has no intention of opening another representation in
Cyprus.

As part of the Commission(cid:146)s efforts to inform the Turkish Cypriot community about the Union, the acquis
and the benefits of membership, the Commission is planning to recruit a Turkish Cypriot local agent, who
will be based in the Delegation in Nicosia under the management of the Head of Delegation.

The Commission is also examining with representatives of the business community, ways and means to
improve the flow of information concerning the Union in the north.

The Government of the Republic of Cyprus supports these initiatives.

(2002/C 40 E/198)

WRITTEN QUESTION E-2090/01

by Jens-Peter Bonde (EDD) to the Commission

Subject: The Sixth Framework Programme for Research in the EU

(13 July 2001)

Why has research into diseases been scaled down under the Sixth Framework Programme for Research,
and why have certain diseases been left out of the programme altogether?

Answer given by Mr Busquin on behalf of the Commission

(24 September 2001)

The Commission does not envisage that disease-related research will be scaled down under the next
Framework Programme compared to the Fifth Framework Programme for Research and technological
development. The proposed budget should actually increase the amount of funding available for such
research.

C 40 E/184

Official Journal of the European Communities

EN

14.2.2002

Disease-related research will be supported strongly in the Specific Programme (cid:145)Integrating and Strengthen-
ing the European Research Area(cid:146) within all areas of the priority theme 1.1.1 (cid:145)Genomics and Biotechnology
for Health(cid:146).

In particular, the following will be addressed under the research priorities listed below:

(i)

(ii)

(cid:145)Fundamental knowledge and basic tools for functional genomics(cid:146), tools and approaches will be
developed, which will lead to a better understanding of and improved treatments for human disease.

(cid:145)Applications of genomics and biotechnology for health(cid:146), genomics and advances in biotechnology will
the development of new diagnostic,
be exploited by supporting technological platforms
preventative and therapeutic tools, which will have implications for a wide range of diseases.

for

(iii) (cid:145)Applications in medicine and public health(cid:146), there will be a concentration of efforts on cancer,
infectious

cardiovascular disease, rare diseases and diseases of the nervous system. Furthermore,
diseases will be tackled by focusing on combating resistance to drugs.

(iv)

(cid:145)Confronting the major communicable diseases linked to poverty(cid:146), the three major communicable
diseases, human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), malaria
and tuberculosis will be addressed in the context of poverty reduction in developing countries.

Disease-related research is also expected to be covered indirectly in the programme component
(cid:145)Anticipating the Community(cid:146)s scientific and technological needs(cid:146) through actions aimed at supporting
the Community public health strategy.

Disease-related research is also likely to benefit
ordination of national research activities under the next Framework Programme.

from the funding proposed for supporting the co-

(2002/C 40 E/199)

WRITTEN QUESTION E-2095/01

by Pat Gallagher (UEN) to the Commission

(13 July 2001)

Subject: EAGGF funds for Connaught, Ulster

Will the Commission provide a full list of EAGGF funding for Connaught, Ulster during the period June
1994 to date?

Answer given by Mr Fischler on behalf of the Commission

(4 September 2001)

The Commission cannot provide a full
list of the European agriculture guidance and guarantee fund
(EAGGF) funding for Connaught, Ulster, during the period from June 1994 to date, due to the fact that the
information on EAGGF funding is available per Member State. The Irish authorities can, certainly, provide
more detailed information.

(2002/C 40 E/200)

WRITTEN QUESTION E-2102/01

by Bart Staes (Verts/ALE) to the Commission

(13 July 2001)

Subject: Subsidies for European oil, gas and coal producers

Between 1975 and 1998, the Commission gave € 747,72 million in subsidies to European oil, gas and coal
producers.